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esults of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of
hronic heart failure IMprove heart fAilure morbidity and mortality?) Study
Objectives The purpose of this study was to assess whether management of heart failure (HF) guided by an individualized
N-terminal pro–B-type natriuretic peptide (NT-proBNP) target would lead to improved outcome compared with HF
management guided by clinical assessment alone.
Background Natriuretic peptides may be attractive biomarkers to guide management of heart failure (HF) and help select patients
in need of more aggressive therapy. The PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart
failure IMprove heart fAilure morbidity and mortality?) study is, to our knowledge, the first large, prospective randomized
study to address whether management of HF guided by an individualized target NT-proBNP level improves outcome.
Methods A total of 345 patients hospitalized for decompensated, symptomatic HF with elevated NT-proBNP levels at ad-
mission were included. After discharge, patients were randomized to either clinically-guided outpatient manage-
ment (n  171), or management guided by an individually set NT-proBNP (n  174) defined by the lowest level
at discharge or 2 weeks thereafter. The primary end point was defined as number of days alive outside the hos-
pital after index admission.
Results HF management guided by this individualized NT-proBNP target increased the use of HF medication (p  0.006),
and 64% of HF-related events were preceded by an increase in NT-proBNP. Nevertheless, HF management
guided by this individualized NT-proBNP target did not significantly improve the primary end point (685 vs. 664
days, p  0.49), nor did it significantly improve any of the secondary end points. In the NT-proBNP–guided group
mortality was lower, as 46 patients died (26.5%) versus 57 (33.3%) in the clinically-guided group, but this was
not statistically significant (p  0.206).
Conclusions Serial NT-proBNP measurement and targeting to an individual NT-proBNP value did result in advanced detection
of HF-related events and importantly influenced HF-therapy, but failed to provide significant clinical improvement
in terms of mortality and morbidity. (Effect of NT-proBNP Guided Treatment of Chronic Heart Failure [PRIMA];
NCT00149422) (J Am Coll Cardiol 2010;56:2090–100) © 2010 by the American College of Cardiology
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Purrent management of patients with heart failure (HF) is
ainly based on clinical signs and symptoms. This approach
llows clinicians to respond to worsening HF once it is
ecognized, but does not allow selection of individuals who are
ost likely to progress to increased morbidity and mortality
nd are thus in need of more intensive treatment. Plasma levels
f B-type natriuretic peptide (BNP) or N-terminal pro-B-type
atriuretic peptide (NT-proBNP) are established indicators of
ecompensated HF (1,2) and predictors of HF morbidity and
ontinuing Medical Education (CME) is available for this article. From the
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etherlands; #Orbis Medical Center, Sittard, the Netherlands; **University Medical
enter, Utrecht, the Netherlands; and ††VieCuri Medical Center, Venlo, the
etherlands. Main funding (€200,000) for this study was provided by the
etherlands Heart Foundation, Netherlands Organisation for Scientific Research
NWO), and the Royal Netherlands Academy of Arts and Sciences (KNAW)–
nteruniversity Cardiology Institute of the Netherlands. Minor funding of an
nrestricted research grant (€70,000 per sponsor) was provided by Pfizer, Astra-
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esearch grants from Roche Diagnostics. All other authors have reported that they
ave no relationships to disclose.S
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ccepted July 6, 2010.ortality (3,4). Natriuretic peptides may therefore be attractive
iomarkers to guide management of HF and help select
atients in need of more aggressive therapy.
See page 2101
Troughton et al. (5) were the first to suggest in a small
ilot study that guiding HF management by aiming for a target
T-proBNP level may improve outcome. In this study, the
nvestigators aimed to achieve NT-proBNP levels of 200
mol/l (1,700 pg/ml) or lower, a goal that is difficult to achieve
n many patients with established HF. The clinical value of
uch stringent (NT-pro)BNP levels has recently been ad-
ressed in several other clinical outcome studies (6–8). These
tudies failed to show an overall reduction in mortality, but did
uggest improved outcome in HF patients under the age of 75
ears. Also, the (NT-pro)BNP target value was achieved only
n a minority of patients. In the STARS-BNP (Systolic Heart
ailure Treatment Supported by BNP) Multicenter study, only
3% reached the BNP target (8), whereas in TIME-CHF
Trial of Intensified vs Standard Medical Therapy in Elderly
atients With Congestive Heart Failure) and the BATTLE-
CARRED (NT-proBNP-Assisted Treatment to Lessen Se-
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Death) trial, at least 50% of the
subjects had not achieved the de-
sired target at the end of the study.
At the same time, the TIME-
CHF investigators speculated that
intensification of therapy might be
harmful in the elderly (7).
As the target NT-proBNP level
in the aforementioned studies was
not achieved in the majority of HF
patients randomized to (NT-
pro)BNP–guided therapy, most
subjects randomized to the (NT-
pro)BNP–guided arms received
intensified treatment. These stud-
ies therefore show that a more
generalized intensification of HF
herapy may be beneficial in specific subgroups. However, it
as not addressed whether serial assessment of NT-proBNP
nables to select patients at risk of increased morbidity and
ortality. Therefore, the question remains whether it is beneficial
o intensify HF therapy only in those patients most likely to
rogress towards events.
It is well known that in many HF patients, NT-proBNP
evels never normalize, whereas these patients still remain
linically stable over years. This suggests that patients with
table NT-proBNP levels (even when clearly elevated) may
ave an acceptable prognosis. We hypothesized that elevation
f outpatient NT-proBNP levels as compared with the
atient’s individualized target level, allows selection of those
F patients most likely to progress towards events. The
ndividualized target level was defined as the lowest level at
ischarge or at 2 weeks follow-up after admission because of
F. We further hypothesized that restricting treatment
ntensification to these selected patients would be beneficial
ithout additional risk of adverse effects. We therefore
erformed a prospective randomized study to address
hether treatment of HF, guided by an individualized
arget NT-proBNP level, improves outcome in HF patients.
ethods
tudy design and study population. To be included,
atients had to be hospitalized for decompensated, symp-
omatic HF, fulfilling the European Society of Cardiology
ESC) diagnostic guideline criteria for acute HF (9). In
ddition, NT-proBNP levels at admission were required to be
t least 1,700 pg/ml, as additional objective evidence of HF (1).
Exclusion criteria were: life-threatening cardiac arrhyth-
ias during the index hospitalization, urgent invasive or surgi-
al intervention performed or planned during the index hos-
ital admission, severe chronic obstructive pulmonary disease
ith a forced expiratory volume in 1 s (FEV1) of 1 l/s,
ulmonary embolism less than 3 months prior to admission,
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BNP  B-type natriuretic
peptide
ESC  European Society of
Cardiology
HF  heart failure
IQR  interquartile range
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
QOL  quality of lifeulmonary hypertension not caused by left ventricular systolic tysfunction, a non–HF-related expected survival of less than 1
ear, and patients undergoing hemodialysis or continuous
mbulant peritoneal dialysis. A lesser degree of renal dysfunc-
ion was not an exclusion criterion. Patients were screened and
ncluded during the index admission because of acute HF (Fig. 1).
nformed consent was obtained and NT-proBNP levels were
easured at hospital discharge. Patients demonstrating a
ignificant decrease in NT-proBNP levels during hospitaliza-
ion, defined as a decrease of more than 10%, with a drop in
T-proBNP levels of at least 850 pg/ml, were randomized to
reatment that was either NT-proBNP guided or clinically
uided. Patients in whom NT-proBNP levels decreased10%
uring admission were considered not to modulate their
T-proBNP levels enough to allow NT-proBNP–guided
reatment. Therefore, these patients were not included. Reg-
lar follow-up visits were scheduled at 2 weeks and 1 month,
nd then every 3 months until the follow-up period of 2 years
as completed. Follow-up visits were performed by dedicated
F cardiologists and nurses. The institutional review board or
thics committee at each site approved the protocol, and all
atients provided written informed consent before enrollment.
Treatment in the NT-proBNP–guided group was guided
y the combination of clinical assessment and NT-proBNP
evels. The individual NT-proBNP target value was set at
he lowest level at discharge or at 2 weeks follow-up. If at
ubsequent outpatient visits, NT-proBNP levels were more
han 10% with a minimum of 850 pg/ml above this
ndividual target level, NT-proBNP level was considered
off-target,” and therapy was intensified according to the
SC HF treatment guidelines (10). In this treatment group,
n electronic case record form indicated at each visit
hether NT-proBNP levels were off-target and indicated
hether intensification was necessary. Therapy in the
linically-guided treatment group was determined by clini-
al assessment alone. A therapy advisor, incorporated in the
lectronic case record form, was designed to give individual
reatment advice, depending on several individual variables
ncluding the cause of HF (ischemic vs. nonischemic), left
entricular ejection fraction (LVEF), clinical signs of HF,
nd creatinine clearance. Also, titration schemes for diuret-
cs, angiotensin-converting enzyme (ACE) inhibitors, beta-
lockers, angiotensin receptor blockers, and aldosterone
eceptor blockers were provided. In the clinically-guided
reatment group, all cardiologists were blinded to the
T-proBNP levels of the patients during follow-up. At
very outpatient visit, vital status was assessed. Quality of
ife (QOL) was assessed at 3-month intervals by the
innesota Living with Heart Failure Questionnaire (11).
T-proBNP levels were measured on a Roche Diagnostics
lecsys platform (Roche Diagnostics Ltd., Rotkreuz, Swit-
erland) at every participating site, except for 1 center where
he NT-proBNP levels of patients randomized to the
T-proBNP guided group were measured within 24 h in a
articipating university hospital nearby.
efinition of study end points. The primary end point ofhe PRIMA (Can PRo-brain-natriuretic peptide guided
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orbidity and mortality?) study was defined as the differ-
nce in total number of days alive and outside the hospital
etween the NT-proBNP–guided and the clinically-guided
roup. This primary end point replaced the initial end point
f reduction in number of events, as the end point of number
f days alive outside the hospital included hospital admission as
ortality. The primary end point was changed before any
atient had been included, in the start-up phase of the study.
ajor secondary end points encompassed total and cardiovas-
ular mortality, total and cardiovascular hospitalization, and
he combined end points of total and cardiovascular morbidity
nd mortality. Furthermore, renal function, left ventricular
ystolic function, and age subgroups were analyzed. Addition-
lly, analysis of the use of evidence-based HF medication was
erformed. Evidence-based HF medication target dose was
efined as the recommended maintenance dose approved for
he treatment of HF in Europe (10). Finally, it was predefined
o analyze the prognostic impact of NT-proBNP levels above
he individually set target level at outpatient visits. All events
ere adjudicated by a blinded event committee, consisting of
Figure 1 Trial Outline
Overview of patients screened, reasons for exclusion, and the total number of patient
insight is given into patients lost to follow-up after 1 year of randomization. COPD  c
NT-proBNP  N-terminal pro–B-type natriuretic peptide; PCI  percutaneous coronary iedical specialists in cardiology, nephrology, vascular medi- aine, pulmonology, and neurology. Serious adverse events
ncluded admissions to the emergency room, hospital admis-
ions, and death.
Treatment in the NT-proBNP group was considered to
e protocol adherent when 1 of the following actions was
ndertaken upon an elevated outpatient NT-proBNP level:
tarting or intensifying HF medication according to the
SC guidelines, all therapeutic and diagnostic actions
earching for underlying causes of HF such as hypertension,
schemic heart disease, valvular heart disease, anemia, and
ardiac arrhythmias; hospital admission (for decompensated
F); or registering for heart transplantation.
tatistical analysis. Based on previous studies and obser-
ations, it was estimated that, with an event rate of 20%, 480
atients would be needed to reach a relative risk reduction in
umber of events of 50% in the NT-proBNP–guided group
ompared with the clinically-guided group at an  level of 0.05
nd a power level of 0.80. Although the primary end point
hanged during the start-up phase of the study, power analysis
emained the same. One year after the first patient being
ncluded, a pre-specified interim analysis was performed, with
omized into the NT-proBNP–guided and the clinically-guided groups. Furthermore,
obstructive pulmonary disease; ICD  implantable cardioverter-defibrillator;
ntion.s rand
hronic
ntervedifference in events (p 0.01) as criterion to preliminary stop
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nalysis demonstrated a pooled event rate of 65%. Thereupon
he power analysis was re-evaluated. It was calculated that 364
atients were needed to demonstrate a minimum reduction in
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristics
NT-proBNP–
(n  17
Baseline
Age, yrs 71.6 12.0
Female 79 (45.4)
Hypertension 83 (47.7)
Diabetes mellitus 44 (25.3)
Transient ischemic attack 8 (4.6)
Stroke 17 (9.8)
COPD 29 (16.7)
Smoking
Current 37 (21.3)
History 56 (32.2)
Atrial fibrillation
Chronic 29 (16.7)
Paroxysmal 28 (16.1)
Coronary artery disease 97 (55.7)
Myocardial infarction 65 (37.4)
PCI 20 (11.5)
CABG 32 (18.4)
Valve replacement 11 (6.3)
Pacemaker 11 (6.3)
ICD 13 (7.5)
History of heart failure
Ischemic 40 (23.0)
Nonischemic 26 (14.9)
Cause unknown 1 (0.6)
Discharge
NYHA functional class
I 20 (11.5)
II 113 (64.9)
III 41 (23.6)
LVEF, % 34.9 13.7
LVEDD, % 57.5 9.6
Mitral regurgitation grade II 84 (48.3)
Systolic BP, mm Hg 116.8 18.5
Diastolic BP, mm Hg 68.7 11.3
Pulse, beats/min 72.1 11.4
QRS duration 116.0
Sodium, mmol/l 139.5 3.2
Potassium, mmol/l 4.27 0.46
Urea, U/l 11.5 (8.2–16
Creatinine, U/l 121 (97.8–1
Hemoglobin, mmol/l 8.5 1.2
NT-proBNP, pg/ml
Admission 8,034 (4,210–
Discharge 2,961 (1,383–
Target 2,491 (1,109–
Follow-up, days 720 (492–7
Values are expressed as mean (SD), n (%), or median (interquartile ra
BP  blood pressure; CABG  coronary artery bypass graft; COPD
defibrillator; IQR interquartile range; LVEDD left ventricular end-dia
NYHA  New York Heart Association; PCI  percutaneous coronary inooled events of 30%. rResults are presented as frequencies, mean (SD), or median
interquartile range [IQR]), where appropriate. Between-
roup comparisons were performed using the t test, Mann-
hitney U test, or chi-square test where appropriate. Event
Clinically-Guided
(n  171) p Value
72.8 (11.7) NS
69 (40.3) NS
84 (49.1) NS
47 (27.5) NS
25 (14.6) 0.002
18 (10.5) NS
30 (17.5) NS
37 (21.6) NS
49 (28.7) NS
29 (17.0) NS
26 (15.2) NS
109 (63.7) NS
74 (43.3) NS
24 (14.0) NS
29 (17.0) NS
9 (5.3) NS
21 (12.3) NS
10 (5.8) NS
33 (19.3)
26 (15.2)
0 NS
17 (9.9)
121 (70.8)
33 (19.3) NS
36.7 14.8 NS
58.5 9.4 NS
63 (36.8) NS
119.4 22.4 NS
69.2 11.6 NS
74.5 (16.1) NS
108.0 NS
139.1 3.8 NS
4.27 0.46 NS
11.9 (9.0–16.0) NS
126 (104.0–166.3) NS
8.4 1.3 NS
1) 8,168 (4,288–14,051) NS
) 2,936 (1,291–5,525) NS
)
699 (464–730) NS
nic obstructive pulmonary disease; ICD  implantable cardioverter-
iameter; LVEF left ventricular ejection fraction; NS not significant;
ion; NT-proBNP  N-terminal pro-B-type natriuretic peptide.Guided
4)
.2)
57.3)
13,83
5,144
4,435
30)
nge).
 chroates for all-cause mortality were estimated by the Kaplan-
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egression analysis. Time-dependent Cox regression analysis
as performed to analyze the prognostic impact of elevated
T-proBNP levels above target value at the outpatient clinic.
ll calculations were performed with the use of the SPSS
tatistical package version 15.0 (SPSS Inc., Chicago, Illinois).
esults
RIMA is a prospective, randomized, single-blind study exe-
uted in 12 Dutch university and large general hospitals.
atients were recruited between June 2004 and September
007. In total, 345 patients were randomized: 174 patients to
he NT-proBNP–guided treatment group and 171 patients to
he clinically-guided group.
Baseline characteristics are shown in Table 1, which did
ot reveal significant differences between the 2 study groups
xcept for the number of transient ischemic attacks (4.6% in
he NT-proBNP–guided vs. 14.6% in the clinically-guided
roup, p  0.002). Patients were elderly with a mean age of
2 years, more than 40% were female, and a large propor-
ion had cardiovascular risk factors such as hypertension and
iabetes mellitus. History of HF was present in 37% of
ubjects, and almost a quarter had a LVEF above 45%. After
he index admission, most patients were in New York Heart
ssociation functional class II at discharge. The median
T-proBNP target value in the NT-proBNP–guided treat-
ent group was 2,491 pg/ml. The median follow-up was 702
Figure 2 Primary End Point: Number of Days Alive Outside the
No significant difference was seen in the primary end point. NT-proBNP  N-terminays (IQR: 488 to 730 days). In 34 patients (17 in both (andomization groups, see Fig. 1), outpatient follow-up visits
fter 1-year follow-up were not completed.
nd points. Management guided by an individualized NT-
roBNP target did not significantly improve the primary end
oint, the number of days alive outside the hospital: median
umber of days alive outside the hospital was 685 versus 664
ays, p  0.49 (Fig. 2). In the NT-proBNP–guided group,
ortality was lower, as 46 patients died (26.5%), versus 57
33.3%) in the clinically-guided group (Fig. 3), but this was not
tatistically significant. The number of scheduled visits did not
iffer between the NT-proBNP–guided and the clinically-
uided group (mean 7.1  3.1 vs. 6.9  3.0, p  0.424).
owever, there was a trend towards an increase in unscheduled
isits in the NT-proBNP–guided group (mean 1.4  1.9 vs.
.1  1.7, p  0.063). The total number of cardiovascular and
F-related admissions between the NT-proBNP–guided and
he clinically-guided groups were not different (mean 1.11 2.20
s. 1.05  1.47, p  0.552, and 0.70  1.89 vs. 0.60 
.25, p  0.989). In addition, none of the other pre-
pecified end points was statistically significantly different
etween the groups (Table 2).
In the subset of patients with left ventricular systolic
ysfunction (ejection fraction below 45%), total mortality
ended to be lower in the NT-proBNP–guided group,
hich however did not attain statistical significance (mor-
ality: 25% in NT-proBNP–guided vs. 33% in usual care, p
.164). In contrast, in patients with preserved left ventric-
lar systolic function, mortality was identical in both groups
ital
–B-type natriuretic peptide.Hosp
al pro31%). Furthermore, in patients under 75 years of age, a
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NT-proBNP–Guided Management of Heart Failure December 14/21, 2010:2090–100rend was seen towards improved outcome in the NT-
roBNP–guided treatment arm (number of days alive outside
ospital as percentage of total follow-up: 87.4% vs. 82.8%, p 
.114). Therapy guided by NT-proBNP levels also tended to be
avorable in patients with lower discharge creatinine levels, but
gain these differences did not attain statistical significance (num-
er of days alive outside hospital as percentage of total follow-up:
2.7% vs. 87.9%, p  0.076).
T-proBNP levels and use of medication. After 1-year
ollow-up, 80% of patients were at or below their individual
arget level. In 23% of all outpatient visits, NT-proBNP
evels were above the individualized target level. In 79% of
ll outpatient visits with an off-target NT-proBNP level,
rotocol adherent action was undertaken (Table 3).
vidence-based medication for HF was extensively used in
oth groups (Table 4). Renin-angiotensin inhibition was
sed significantly more frequently after 1 year in the
T-proBNP–guided group. Management guided by an
ndividualized NT-proBNP target also led to an overall
ncreased use of HF medication (Table 5). An increased
T-proBNP value most often prompted physicians to
ntensify diuretic therapy. The lack of significant beneficial
utcomes suggests that intensifying diuretic therapy may
ot be adequate to prevent events. We therefore compared
he effects of intensifying evidence-based HF medication
i.e., increase renin-angiotensin system blockade, beta-
lockade, and spironolactone) to the effect of intensifying
Figure 3 Survival in the NT-proBNP–Guided
and the Clinically-Guided Groups
Survival of patients with heart failure receiving treatment guided by an individu-
alized NT-proBNP target level (blue line) or treatment guided by clinical assess-
ment alone (red line). NT-proBNP  N-terminal pro–B-type natriuretic peptide.iuretics in response to an increased NT-proBNP level. gowever, no differences were found between the 2 types of
reatment in ability to increase the number of patients on or
elow target level at the next outpatient follow-up (40% vs.
3%, p  0.369). Moreover, in general, intensifying HF
edication (evidence-based HF medication or diuretics) com-
ared with no pharmacological HF intervention was not
ssociated with a significantly higher number of patients who
eached their NT-proBNP target (47% vs. 36%, p  0.117).
During follow-up, NT-proBNP levels and levels of urea
nd creatinine did not significantly differ between both
reatment groups, although there was a trend for increased
reatinine in the NT-proBNP–guided group (Table 6).
lso, no difference was seen in QOL between the NT-
roBNP–guided and the clinically-guided groups: median
OL at discharge: 47 (IQR: 34 to 62) versus 48 (IQR: 36 to
0), p  0.95, at 6-month follow-up: 23 (IQR: 10 to 39)
ersus 25 (IQR: 11 to 42), p  0.64, and at 12-month
ollow-up: 20 (IQR: 6 to 36) versus 23 (IQR: 10 to 38), p 0.6.
The individualized NT-proBNP target value appeared to
e of prognostic importance. Most HF-related events (64%)
ere preceded by off-target NT-proBNP levels at previous
utpatient follow-up. Outpatient elevation of NT-proBNP
evels above this individualized target value indicated an
ncreased risk for major end points such as total mortality
hazard ratio [HR]: 1.84, p  0.007), cardiovascular mor-
ality (HR: 2.53, p  0.001), and HF-related mortality
HR: 3.69, p  0.001) (Table 7).
iscussion
he PRIMA study is a prospective randomized study to
ddress whether HF therapy, guided by an individualized
T-proBNP level, improves outcome in HF patients.
The PRIMA study randomized 345 patients to HF
herapy guided by an individually set NT-proBNP target
evel in addition to clinical signs, or by clinical signs only. It
ddressed the benefit of selective intensification of therapy
nly when NT-proBNP increases beyond the individually
efined “optimal” NT-proBNP level. Assessing the opti-
um natriuretic peptide target level is most challenging
12). As such, the PRIMA study complements the recent
tudies on the benefits of a more general intensification of
herapy by aiming for absolute NT-proBNP targets (6,7).
PRIMA showed that selective intensification by an indi-
idualized NT-proBNP target did not significantly improve
ny of the pre-specified primary or secondary outcome
easures. Although treatment guided by an individualized
T-proBNP target slightly improved the number of days
live outside the hospital, and improved overall mortality,
hese changes were not statistically significant.
Individualized NT-proBNP–guided therapy resulted in sig-
ificantly intensified pharmacological HF therapy reflected by
n increased use of diuretics and ACE inhibitors or angioten-
in II receptor antagonists in the NT-proBNP–guided group.
We hypothesized that individualized NT-proBNP–
uided treatment would improve outcome. Our first as-
Secondary Outcome MeasuresTable 2 Secondary Outcome Measures
Days Alive Outside the Hospital* Mortality CV Mortality Days Admitted to the Hospital†
n Mean, % (SD) Median, % (IQR) p Value n (%) Log-Rank p Value n (%) Log-Rank p Value Mean, % (SD) Median, % (IQR) p Value
Total group
NT-proBNP–guided 174 81.3 (31.6) 99.0 (74.4–100.0) 0.174 46 (26) 0.206 34 (20) 0.705 5.09 (9.94) 0.68 (0.00–4.56) 0.490
Clinically-guided 171 79.2 (32.0) 98.5 (64.4–99.9) 57 (33) 36 (21) 4.46 (8.67) 0.93 (0.14–4.62)
LVEF 45%
NT-proBNP–guided 112 83.5 (29.1) 99.2 (82.2–100.0) 0.140 28 (25) 0.164 20 (18) 0.439 5.26 (10.8) 0.48 (0.00–4.42) 0.334
Clinically-guided 117 78.2 (31.1) 98.6 (57.3–99.9) 39 (33) 25 (21) 5.13 (9.93) 0.93 (0.07–0.51)
LVEF 45%
NT-proBNP–guided 42 75.2 (36.6) 97.3 (42.8–99.7) 0.946 13 (31) 0.861 12 (29) 0.421 5.92 (9.35) 1.67 (0.16–8.52) 0.760
Clinically-guided 42 82.1 (29.8) 98.0 (82.3–99.6) 13 (31) 9 (21) 3.32 (5.00) 1.04 (0.30–4.73)
Discharge NT-proBNP 2,950 pg/ml
NT-proBNP–guided 87 74.7 (34.6) 97.5 (43.8–99.7) 0.325 31 (36) 0.139 21 (24) 0.504 6.61 (10.51) 2.19 (0.17–8.47) 0.897
Clinically-guided 85 69.1 (35.6) 92.9 (33.6–99.5) 41 (48) 24 (28) 6.28 (10.57) 1.23 (0.16–7.91)
Discharge NT-proBNP 2,950 pg/ml
NT-proBNP–guided 87 88.0 (26.9) 99.7 (96.8–100.0) 0.248 15 (17) 0.845 13 (15) 0.853 3.58 (9.15) 0.24 (0.00–2.05) 0.196
Clinically-guided 86 89.2 (24.4) 99.2 (95.4–99.9) 16 (19) 12 (14) 2.66 (5.75) 0.55 (0.00–3.16)
Age  median 74 yrs
NT-proBNP–guided 92 87.4 (26.4) 99.5 (95.4–100.0) 0.114 17 (18) 0.225 13 (14) 0.653 4.40 (10.08) 0.37 (0.00–2.71) 0.138
Clinically-guided 81 82.8 (30.9) 98.7 (88.6–99.9) 21 (26) 13 (16) 3.85 (7.79) 0.93 (0.14–3.83)
Age  median 74 yrs
NT-proBNP–guided 82 74.5 (35.6) 97.9 (42.2–99.9) 0.908 29 (35) 0.745 21 (26) 0.874 5.88 (9.79) 1.23 (0.10–7.83) 0.587
Clinically-guided 90 76,0 (32.8) 96.6 (50.6–99.8) 36 (40) 23 (26) 5.00 (9.40) 0.88 (0.10–4.96)
Discharge creatinine 123 U/l
NT-proBNP–guided 85 92.7 (19.4) 99.7 (97.8–100.0) 0.076 11 (13) 0.198 7 (8) 0.157 2.33 (6.77) 0.27 (0.00–1.39) 0.116
Clinically-guided 80 87.9 (25.9) 99.4 (96.4–100.0) 16 (20) 12 (15) 2.49 (5.92) 0.55 (0.00–2.71)
Discharge creatinine 123 U/l
NT-proBNP–guided 81 71.3 (35.8) 95.4 (37.0–99.6) 0.742 32 (40) 0.656 24 (30) 0.561 6.92 (10.2) 2.33 (0.16–9.82) 0.804
Clinically-guided 82 71.0 (35.3) 93.0 (33.8–99.3) 37 (45) 21 (26) 6.54 (10.6) 1.85 (0.17–8.41)
All reported data demonstrate no significant differences in outcome between the NT-proBNP–guided group and the clinically-guided group. *The number of days alive outside the hospital as a percentage of total days of follow-up; †days admitted to the hospital as a percentage
of total days alive.
Abbreviations as in Table 1.
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n improved prognosis, even when the stable NT-proBNP
evel is well above normal. This first assumption was
onfirmed in this study. Patients who maintained their
ndividual NT-proBNP target level indeed had a highly
ignificantly better outcome. Most events occur in patients
ith an unstable NT-proBNP. Indeed, increases of NT-
roBNP level above each individual optimum was a strong
redictor of HF-related events with hazard ratios up to 4.17,
 0.001. Our second assumption was that treatment of HF
esponse to ElevatedT-pr BNP Lev ls During Follow-UpTable 3 Response to ElevatedNT-proBNP Levels During Follow-Up
Drug intervention*
Diuretics 109 (40.5)
ACE inhibitors 17 (6.3)
Beta-blockers 30 (11.2)
Digoxin 9 (3.3)
Aldosteron antagonists 11 (4.1)
AT2 antagonists 11 (4.1)
Nitrates 10 (3.7)
Alpha-blocker 1 (0.4)
Anti-arrythmic agent 1 (0.4)
Hydralazine 1 (0.4)
Decrease calcium-channel blocker 2 (0.7)
Total change medication 202 (75.1)
Diagnostics
Echocardiogram 8 (3.0)
Ischemia† 6 (2.2)
Holter monitoring 7 (2.6)
Consultation‡ 5 (1.9)
Chest X-ray 2 (0.7)
Total diagnostics 28 (10.4)
Other interventions
Admission because of heart failure 18 (6.7)
Admission emergency department 1 (0.4)
Pacemaker implantation 1 (0.4)
ICD implantation 2 (0.7)
Admission other 2 (0.7)
Heart revalidation 1 (0.4)
Analysis/treatment anemia 3 (1.1)
Information way of life 2 (0.7)
Electro cardioversion 4 (1.5)
Total other interventions 34 (12.6)
Total interventions 234
No intervention
No treatment options 5 (1.9)
Patient on dialysis 2 (0.7)
Severe hypotension 1 (0.4)
No valid reason given 46 (17.1)
No NT-proBNP at disposal 1 (0.4)
Intervention refused by patient 1 (0.4)
Total no intervention 56 (20.8)
Total elevated NT-proBNP levels 269 (100.0)
alues are n (%). *Except for calcium-channel blockers, drug intervention concerns the start or
ncrease of medication, or change in type of medication. †MIBI stress test, coronary angiography,
r exercise test. ‡Specialized cardiologist/internal medicine/other.
ACE angiotensin-converting enzyme; AT2 angiotensin II; NT-proBNP N-terminal pro–B-type
atriuretic peptide.uided by an individualized target NT-proBNP level could Us T
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December 14/21, 2010:2090–100 NT-proBNP–Guided Management of Heart Failurevert HF events. Despite the ability to detect 64% of the
mminent events, and despite the subsequent intensification of
F medication, events were not significantly averted. This
uggests that although NT-proBNP measurement can help
etect worsening HF, current standard-of-care HF therapy is
nable to avert subsequent events. NT-proBNP levels react
pon ventricular wall stretch (13). Therefore, deterioration of
F is needed before levels rise. Elevated marker levels before
n increase in cardiac pressures takes place might help us
dentify patients at risk for events; in such an early phase,
edical intervention can still avert worse outcome. NT-
roBNP appears to be a “passenger-seat” marker: you can see
hich direction your car is heading, but you are not in control
f the steering wheel. In order to reduce morbidity and
ortality, a “driver-seat” marker is urgently needed.
A number of reasons may account for this lack of significant
mprovement. First, not enough events during follow-up may
ave been detected, as 36% of events were undetected by
easurement of NT-proBNP at 3-month intervals. Second,
ntensification of treatment against a background of high use of
vidence-based HF therapy may not suffice to avert an immi-
ent event. Third, current “gold-standard” HF therapy may
ltogether be inadequate in preventing HF-related events in
atients with deterioration of HF.
ubgroups analyzed. The effects of NT-proBNP guidance
eemed mitigated in patients with preserved systolic func-
ion, although differences did not reach statistical signifi-
ance. The lack of well-established medical or other inter-
ention measures for patients with preserved ejection
raction HF may limit the success of interventions prompted
y off-target NT-proBNP in this group.
The effects of NT-proBNP guidance seemed more favor-
ble in younger patients (age under 75 years) and those with
umber of Increases of HFedicati n During Follow-UpTable 5 Numb r of Increases of HFMedication During Follow-Up
NT-proBNP–Guided
(n  174)
Clinically-Guided
(n  171) p Value
Diuretics 168 120 0.02
Beta-blockers 105 95 0.35
ACE inhibitors 77 55 0.1
AT2 antagonists 41 22 0.39
Aldosterone antagonists 19 15 0.86
Digoxin 14 19 0.63
Total 424 326 0.006
bbreviations as in Tables 3 and 4.
hanges in NT-proBNP, Urea, and Creatinine Levels During Follow-UTable 6 Changes in NT-proBNP, Urea, and Creatinine Levels Du
Dynamic Changes During
Follow-Up
6-Month Follow-Up
NT-proBNP–Guided Clinically-Guided
NT-proBNP, pg/ml 254 (1,415 to 530) 287 (1,186 to 688
Urea, mmol/l 0.5 (3.8 to 2.6) 0.8 (3.3 to 1.2)
Creatinine, mol/l 7.00 (12.0 to 32.0) 2.0 (15 to 19)alues are expressed as median (interquartile range).
NT-proBNP  N-terminal pro–B-type natriuretic peptide.etter renal function, although these differences also did not
each statistical significance. Both younger patients and
atients with preserved renal function have less comorbidity,
nd are expected to better tolerate intensification of therapy.
t is these type of patients that have been included in most
andmark trials that yielded the evidence for HF therapy.
lderly patients with severe renal dysfunction and patients
ith preserved left ventricular systolic function HF form the
ajority of HF patients, but they are underrepresented in
andmark trials (14). Therefore, speculatively, it seems that
he intensified use of evidence-based HF therapy is mainly
ffective in the subgroups where this evidence was obtained.
Previous studies have demonstrated that NT-proBNP
evels fall in response to optimizing HF therapy (15–17). In
RIMA, intensifying HF therapy in patients with rising
T-proBNP levels failed to lower these levels.
The lack of benefit seen in our study is in line with the
verall lack of benefit seen with studies of NT-proBNP–
uided therapy by an absolute NT-proBNP target (6,7).
RIMA shows that treatment of HF guided by an individ-
alized NT-proBNP target against a background of optimal
F therapy does not have additional beneficial effects.
tudy limitations. As opposed to what could be expected
rom large HF surveys (18), only a minority of patients
ncluded in our study had a history of HF. NT-proBNP
evels might decrease more in response to HF treatment in
atients with de novo HF compared with patients with a
istory of HF and background therapy before admission.
ecause we excluded patients if NT-proBNP levels de-
reased 10%, with a minimum of 850 pg/ml, more
atients with a history of HF and prolonged exposure to
herapy might be excluded than patients with de novo HF.
Power analysis was based on the initial primary end point
f reduction in events. Sample size was calculated to
emonstrate a minimum reduction in pooled events of 30%.
Follow-Up
12-Month Follow-Up
p Value NT-proBNP–Guided Clinically-Guided p Value
0.60 432 (1,392 to 297) 572 (1,329 to 434) 0.99
0.41 0.0 (3.8 to 2.2) 1.0 (4.1 to 1.7) 0.16
0.06 8.0 (10.3 to 31.8) 3.0 (14.0 to 22.0) 0.07
ime-Dependent HR if the Outpatient NT-proBNPev l Is Above the Individ ally Set Target ValueTable 7 Time-Dependent HR if the Outpatient NT-proBNPLevel Is Above the Individually Set Target Value
n (%) HR 95% CI p Value
Total mortality 103 (29.9) 1.84 1.18–2.85 0.007
CV mortality 70 (20.3) 2.53 1.52–4.21 0.001
HF mortality 45 (13.0) 3.69 2.02–6.72 0.001
First CV admission 193 (55.9) 2.70 1.96–3.73 0.001
First HF admission 115 (33.3) 4.17 2.84–6.13 0.001
I confidence interval; CV cardiovascular; HF heart failure; HR hazard ratio; NT-proBNP
-terminal pro–B-type natriuretic peptide.pring
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NT-proBNP–Guided Management of Heart Failure December 14/21, 2010:2090–100post hoc power analysis indicated that a difference of 4%
n percentage of time (approximately 28 days) alive outside
he hospital could have been detected.
One may surmise that choosing an individual (often elevated)
T-proBNP target is not accurate enough, and that more
tringent targets should be aimed for in all subjects. However, the
rognostic impact we observed of NT-proBNP levels above the
ndividual target, even when the target is clearly elevated, argues
gainst this notion. Furthermore, the most common reaction to an
levated NT-proBNP level was to increase dosage of diuretics.
e have not been able to demonstrate the ability of any subtype
f intervention (evidence-based medication, diuretics, or nonphar-
acologic) to be more effective in lowering off-target NT-
roBNP levels. The use of our electronic therapy advisor might
ave lead to more intensified treatment in the clinically-guided
roup than would occur in daily practice where such advices are
ot generated.
Previous studies have demonstrated that discharge NT-
roBNP levels, decrease in NT-proBNP levels during admis-
ion because of HF, and outpatient NT-proBNP levels in
atients with stable, chronic HF were of prognostic impor-
ance (4,19,20). The possible additive value of a combination
f static and dynamic NT-proBNP levels for determining
ndividual prognosis still remains to be assessed.
onclusions
his is the first study to our knowledge that evaluated whether
F therapy guided by an individualized NT-proBNP target
evel improves outcome. PRIMA shows that unstable NT-
roBNP levels indeed indicate imminent events, but that
ntensification of currently used medication in patients on
ptimal HF therapy does not prevent further deterioration.
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